Market Place
Sourcing Support
Outlook Therapeutics® Joins Virtual Investor CEO Connect Segment
17 Oct 2024 //
GLOBENEWSWIRE
Outlook Therapeutics To Join Virtual Investor Closing Bell
16 Sep 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Attends Chardan Virtual Ophthalmology Conference
13 Sep 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Completes NORSE EIGHT Trial Enrollment
04 Sep 2024 //
GLOBENEWSWIRE
Outlook Therapeutics to Present at H.C. Wainwright Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Q3 FY 2024 Financial Results And Corporate Update
14 Aug 2024 //
GLOBENEWSWIRE
Outlook Therapeutics To Present At H.C. Wainwright Conference
12 Aug 2024 //
GLOBENEWSWIRE
Outlook Therapeutics To Report Q3 FY 2024 Results On August 14
07 Aug 2024 //
GLOBENEWSWIRE
Outlook Therapeutics To Present At BTIG Virtual Biotechnology Conference
30 Jul 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Announces UK MHRA Approval Of LYTENAVA™ For Wet AMD
08 Jul 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
11 Jun 2024 //
GLOBENEWSWIRE
Outlook Therapeutics: EU Approval For LYTENAVA Wet AMD Treatment
28 May 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Q2 Fiscal 2024 Results, Corporate Update
15 May 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Submits UK MAA For ONS-5010 As Wet AMD Treatment
13 May 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Q2 FY2024 Results On May 16
09 May 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® to Present at the Retina World Congress 2024
02 May 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® at OIS Retina Innovation Showcase
29 Apr 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® $5M Private Placement Closing
15 Apr 2024 //
GLOBENEWSWIRE
Outlook® Receives European Union Positive CHMP Opinion for ONS-5010
22 Mar 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® Announces Closing of Private Placement of up to $159M
18 Mar 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
12 Mar 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year
14 Feb 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
31 Jan 2024 //
GLOBENEWSWIRE
Outlook Therapeutics Receives FDA Agreement Under SPA for Study, NORSE EIGHT
23 Jan 2024 //
GLOBENEWSWIRE
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023
22 Dec 2023 //
GLOBENEWSWIRE
Outlook Therapeutics Submits SPA to FDA for Non-Inferiority Study of ONS-5010
19 Dec 2023 //
GLOBENEWSWIRE
Outlook Therapeutics® Announces Strategic Organizational Realignment
06 Dec 2023 //
GLOBENEWSWIRE
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes
27 Nov 2023 //
GLOBENEWSWIRE
Outlook Adds Expertise with Appointment of Jedd Comiskey as Senior VP
14 Nov 2023 //
GLOBENEWSWIRE
Outlook to conduct another trial for wet AMD drug; Cara strikes new royalty deal
03 Nov 2023 //
ENDPTS
Outlook Therapeutics® Provides Update on Type A Meetings with FDA
02 Nov 2023 //
GLOBENEWSWIRE
Outlook Therapeutics® to Present at Guggenheim™s 5th Annual INI Conference
01 Nov 2023 //
GLOBENEWSWIRE
Outlook Therapeutics® Requests Type A Meeting With FDA
29 Sep 2023 //
GLOBENEWSWIRE
Outlook to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
21 Sep 2023 //
GLOBENEWSWIRE
Outlook to Present at H.C. Wainwright 25th Annual Global Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
FDA rejected Outlook Therapeutics` Lucentis rival, & the company`s stock plunged
31 Aug 2023 //
ENDPTS
Outlook Therapeutics Reports Financial Results for Q3 Fiscal Year 2023
14 Aug 2023 //
GLOBENEWSWIRE
Outlook Therapeutics® to Present at BTIG Virtual Biotechnology Conference 2023
01 Aug 2023 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Financial Results for 2Q Fiscal Year 2023
15 May 2023 //
GLOBENEWSWIRE
Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference
27 Apr 2023 //
GLOBENEWSWIRE
Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank
13 Mar 2023 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Financial Results for Q1 Fiscal Year 2023
14 Feb 2023 //
GLOBENEWSWIRE
Outlook to Present at the SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
Outlook Therapeutics Appoints Surendra Sharma as Senior Vice President
19 Jan 2023 //
GLOBENEWSWIRE
Outlook to Present at the Virtual Investor 2023 Companies to Watch Event
09 Jan 2023 //
GLOBENEWSWIRE
Outlook Therapeutics Announces $25 M Registered Direct Offering
23 Dec 2022 //
GLOBENEWSWIRE
Outlook Therapeutics® Enters Definitive Agreement for $31.8 M Convertible Note
23 Dec 2022 //
GLOBENEWSWIRE
Outlook Therapeutics® Announces Validation of MAA by theEMA for ONS-5010
22 Dec 2022 //
PRESS RELEASE
Outlook Therapeutics® Announces Validation of MAA by the EMA for ONS-5010
22 Dec 2022 //
GLOBENEWSWIRE
Outlook Therapeutics to Participate in Cantor Fitzgerald Medical & Aesthetic
01 Dec 2022 //
GLOBENEWSWIRE
Outlook Therapeutics to Present at the BTIG Ophthalmology Day
22 Nov 2022 //
GLOBENEWSWIRE
Outlook Announces Acceptance of Biologics License Application byFDA for ONS-5010
28 Oct 2022 //
GLOBENEWSWIRE
Outlook ®and AmerisourceBergen Announce Strategic Agreement for ONS-5010
27 Sep 2022 //
GLOBENEWSWIRE
Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual GIC
07 Sep 2022 //
GLOBENEWSWIRE
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010
30 Aug 2022 //
GLOBENEWSWIRE
Outlook Therapeutics Appoints Julia A. Haller, MD in Board of Directors
15 Aug 2022 //
GLOBENEWSWIRE
Outlook Therapeutics Reports Financial Results for 3rd Quarter Fiscal Year 2022
10 Aug 2022 //
GLOBENEWSWIRE
Outlook Txs Announces Full Cash Pre-Payment of Convertible Promissory Note
05 Jul 2022 //
GLOBENEWSWIRE
Outlook Therapeutics Confirms Status of BLA Submission for ONS-5010
14 Jun 2022 //
GLOBENEWSWIRE
Microcap`s effort to take on Eylea with Avastin biosimilar faces FDA roadblock
01 Jun 2022 //
ENDPTS
